Accelerate Diagnostics (AXDX) Receives a Buy from Piper Jaffray


Piper Jaffray analyst William Quirk reiterated a Buy rating on Accelerate Diagnostics (NASDAQ: AXDX) yesterday and set a price target of $24. The company’s shares closed yesterday at $21.80.

According to TipRanks.com, Quirk is a 5-star analyst with an average return of 18.5% and a 69.5% success rate. Quirk covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Idexx Laboratories, and Becton Dickinson.

Accelerate Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $24.50.

See today’s analyst top recommended stocks >>

Based on Accelerate Diagnostics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.23 million. In comparison, last year the company had a GAAP net loss of $16.46 million.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXDX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts